Notícias

RapAdmin

SILtheory
SILtheory2752×1536 357 KB

This narrative review from three Italian immunologists proposes the “Silent Infection Load” (SIL) hypothesis. It argues that the lifelong total of infections that cause no symptoms contributes to inflammaging, the chronic low-grade inflammation of old age. These include common respiratory viruses, mild gut infections, herpesviruses that wake up without symptoms, colonizing bacteria, and low-level leakage of microbes across damaged barriers. The authors say each event causes a small, contained burst of immune activity. That burst stresses blood vessel linings, fragments mitochondria, activates complement, and disturbs stem cells. Repair is incomplete each time, so the damage adds up over decades. They present this as an evolutionary trade-off. Tolerating microbes helped people survive early in life, and the cost only shows up in the long lives people live today. The authors say openly that most of the evidence is indirect, and they propose vaccination as the main way to test the idea and act on it.

Most of us think of infection as an event: a fever, a lost week, then recovery. A new review from three Italian immunologists argues that the infections that matter most for aging may be the ones we never feel.

Andrea Cossarizza of the University of Modena and Reggio Emilia and colleagues call their idea the Silent Infection Load. Over a lifetime, the body quietly fights off a near continuous stream of microbes. These include rhinoviruses and seasonal coronaviruses, stomach bugs that never get past a queasy afternoon, herpesviruses such as cytomegalovirus and Epstein-Barr virus that sleep in our cells and periodically wake, and bacteria living on skin, gums and mucosa. The authors argue that each encounter triggers a small, contained burst of immune activity, which they call a micro-storm.

A micro-storm never raises a fever. According to the review, though, it does raise signalling molecules such as IL-6 and TNF, loosen the seals between cells lining small blood vessels, fragment mitochondria, and switch on complement, a cascade of blood proteins that tags and attacks invaders. Each episode clears, but the authors contend repair is rarely complete. A slightly leakier vessel, a more damaged mitochondrion, a stem cell pushed out of its resting state one more time: over decades, these leftovers could add up to the inflammation that feeds frailty, heart disease and dementia. The process may also feed itself. An aging immune system controls latent viruses less well, which means more reactivations and more inflammation.

The evolutionary framing is the most interesting part. Wiping out every microbe would cost too much energy and cause too much collateral damage, so tolerating some persistence was the affordable strategy. Few ancestral humans lived long enough for the late-life bill to arrive. Now most of us do. On this view, inflammaging is not the immune system breaking down. It is the running cost of a design built for a shorter life.

The practical angle is vaccination. If silent infections are part of the problem, preventing them should slow inflammaging. The authors cite evidence linking shingles vaccination to lower dementia rates. They also argue that a future cytomegalovirus vaccine could matter more for aging than for infection control.

The caveats are large, and to their credit the authors state them. Almost no evidence comes from people followed over time with truly silent infections. Most of it is borrowed from severe infections, cell culture and animal work, then extrapolated downward. Their own grading rates only latent herpesviruses as strongly supported. They also present the silent load as an amplifier of other aging drivers, not a main cause.

Field data complicate the picture further. The Tsimane of Bolivia carry heavy infection burdens and high inflammatory markers, yet they have some of the lowest rates of coronary artery disease ever measured. More infection does not straightforwardly mean worse aging.

What the review offers is a testable agenda. Build an index of lifetime silent infection from antibody profiling and blood markers, track it in aging cohorts, and use vaccine rollouts as experiments. Until then, the Silent Infection Load is a well-argued hypothesis, not a finding.

Actionable Insights

This is a review with no new data, so any benefits come from the human studies it cites, not from the paper itself.

  1. Get the recombinant shingles vaccine if you are eligible. This is the strongest actionable signal. In a natural experiment in Wales, people who became eligible for shingles vaccination were about 20% less likely (relative) to receive a new dementia diagnosis over 7 years, roughly 3.5 fewer diagnoses per 100 people. A separate US records study found about 17% more dementia-free time over 6 years with the recombinant vaccine than with the older live vaccine. That works out to roughly five extra months without a diagnosis. [Confidence: Medium. The Welsh design is unusually strong for observational data, but the mechanism is unproven.]
  2. Stay current on influenza, RSV (older adults) and pneumococcal vaccines. These reduce symptomatic disease and some silent carriage or shedding. No trial has yet shown that they slow inflammaging itself. [Confidence: Low for the aging benefit.]
  3. Take periodontal health seriously. Gum pathogens are one of the more plausible sources of chronic low-grade systemic inflammation, but the evidence is associative. [Confidence: Low to Medium.]
  4. Cytomegalovirus has no vaccine yet. Its association with mortality in older adults is real but modest and confounded, so there is no clinical action for it today.

Context and Source

  • Open Access Paper: The silent infection load: How lifelong asymptomatic infections may contribute to inflammaging as an evolutionary trade-off of longevity, 3 September 2026.
  • Institutions: University of Modena and Reggio Emilia; IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, Milan; IRCCS Fondazione Don Carlo Gnocchi, Milan; University of Milan
  • Country: Italy
  • Journal: Ageing Research Reviews
  • Impact evaluation: The impact score of this journal is 15.5 (2025 Journal Impact Factor, 2026 JCR release; CiteScore 20.6), evaluated against a typical high-end range of 0 to 60+ for top general science and review journals, therefore this is a High impact journal.

Leitura Relacionada:

RapAdmin

ChildhoodLongevity
ChildhoodLongevity2752×1536 436 KB

This review proposes the “Adaptive Cost Hypothesis”: many non-communicable diseases (heart disease, type 2 diabetes, cancer, dementia) are not mainly lifestyle-mismatch diseases but the delayed costs of biological settings that helped our ancestors survive to reproduce. Early-life adversity is argued to tune immune, metabolic, stress and oxytocin systems through DNA methylation. These settings pay off in youth and do damage when they run for 70 to 90 years. The authors support the idea with evidence from hunter-gatherer populations, epigenetic clocks, childhood adversity studies and a 2026 mouse sepsis experiment. They recommend moving prevention toward pregnancy and early childhood and redefining healthy ageing as preserved function rather than normal lab values.

Why do people who do everything right still get heart disease, diabetes and dementia? A new review from the Luxembourg Institute of Health argues that the usual answer, that modern lifestyles clash with Stone Age bodies, is only half the story. The other half, say Jonathan Turner and colleagues, is that much chronic disease is the delayed bill for biological settings that helped our ancestors survive long enough to have children.

They call it the Adaptive Cost Hypothesis. It builds on an old idea from evolutionary biology. Selection cares about reproduction, so traits that help you survive to 30 are favoured even if they cause trouble at 75. The authors combine this with evidence that early experience tunes the body through chemical tags on DNA. A child who grows up with threat, hunger or neglect may develop a hair-trigger immune system, a reactive stress axis, a weaker oxytocin system and a metabolism built to store calories. In a dangerous world these settings help. Run them for eight decades and, the authors argue, you get chronic inflammation, stiff arteries, insulin resistance and overactive brain immune cells that feed dementia.

The central claim is that this is not just mismatch. Even when adult life matches what childhood programming expected, the programme itself wears the body down, because nothing selected it to run that long.

The supporting evidence is indirect and drawn from many sources. The Tsimane of Bolivia, forager-farmers who are lean and very active, have some of the cleanest arteries ever measured, yet some coronary calcium and dementia still appear with age. Epigenetic clocks track age closely even in healthy people. Adults with hard childhoods show more inflammation, altered methylation of the oxytocin receptor gene and more heart disease decades later. A 2026 Nature mouse study adds a molecular example: a heart pathway that protects young mice during sepsis kills old mice, and blocking it saved old animals while harming young ones.

The authors draw practical conclusions. Prevention should move upstream to prenatal care, support for new parents and reducing childhood adversity, and methylation clocks should be used to judge within a few years whether such programmes work. Healthy ageing, they argue, should mean keeping independence and a clear mind, not chasing perfect blood numbers. Therapies aimed at ageing itself, such as senolytics or partial reprogramming, fit the logic better than treating each disease one at a time.

The weaknesses are substantial. The paper contains no new data. Several of the studies it relies on do not test what it implies. The CALERIE diet trial never measured early-life programming, and the Look AHEAD lifestyle trial did not compare early with late intervention. Epigenetic clocks are built to predict age, so their accuracy says little about whether ageing is programmed. The authors’ own source on hunter-gatherer lifespans reports that the most common adult age at death in those groups is around 70, which undercuts the claim that human biology was “designed” for 40 to 60 years.

Even so, the paper asks a useful question in testable form: how much late-life disease can lifestyle realistically prevent, and how much is set early? The answer matters for where prevention money goes.

Actionable Insights

  1. Lifestyle still does most of the work you can control. The Tsimane are the paper’s best example of an intrinsic “floor,” yet about 85% of Tsimane adults had zero coronary artery calcium. That is a very large protective effect from diet and activity, and it is the modifiable part of risk.
  2. Treat a difficult childhood like a family history. People with four or more adverse childhood experiences have roughly twice the odds of heart disease and cancer as people with none. If your baseline heart disease risk is 6%, doubling the odds puts you at about 11 to 12%. That justifies earlier checks of blood pressure, lipids, glucose and inflammatory markers.
  3. For parents and policymakers, early investment may have unusually large returns. In the small Abecedarian early-childhood trial, men who received the program had systolic blood pressure about 17 points lower in their mid-30s. The sample was small, so treat this figure as optimistic.
  4. Do not expect midlife weight loss alone to erase cardiovascular risk. In Look AHEAD, sustained weight loss improved blood sugar and fitness but did not measurably reduce heart attacks or strokes over about 10 years.
  5. Aim for function (strength, cognition, independence) over perfect lab numbers.

Context and Source

  • Open Access Paper: Living beyond our evolutionary warranty: Why non-communicable diseases may be the inevitable costs of an extended lifespan, November 2026.
  • Institutions: Luxembourg Institute of Health, Department of Infection and Immunity (Luxembourg); Swedish University of Agricultural Sciences, Department of Animal Environment and Health (Sweden)
  • Countries: Luxembourg and Sweden
  • Journal: Ageing Research Reviews
  • Impact evaluation: In the 2026 Journal Citation Reports release, based on 2025 citation data, the journal’s impact factor is 15.5, it ranks third of 72 journals in Geriatrics and Gerontology, and its Elsevier CiteScore is 20.6 therefore this is a High impact journal.

Leitura Relacionada:

RapAdmin

AirPollutionAccelAging
AirPollutionAccelAging2752×1536 425 KB

This review from Tampere University and Karolinska Institutet brings together evidence that air pollution speeds up biological aging itself, not just damage to one organ at a time. Fine and ultrafine particles, traffic exhaust and smoke from indoor solid-fuel cooking are linked to oxidative stress, inflammaging, mitochondrial damage, telomere erosion and cellular senescence. The strongest human signals appear in composite blood-chemistry measures (Klemera-Doubal biological age, PhenoAge) and frailty indices. Epigenetic clocks are the notable exception: they fail at the meta-analytic level. The authors argue that biological aging partly mediates the link between pollution and death, disease and hospitalization. Switching to clean cooking fuels and improving regional air quality are associated with partial reversal. Get N95 masks if you live in an area where forest fires are common.

Most people think of air pollution as a lung problem, or at most a heart problem. A new review from researchers in Finland and Sweden argues that this view is too narrow. They propose that fine particles, traffic exhaust and smoke from indoor cooking fires act on the machinery of aging itself. On this account, pollution pushes the whole body toward an older physiological state instead of damaging one organ at a time.

Parinaz Poursafa and Juulia Jylhävä collected epidemiological and laboratory work across every major way scientists now measure biological age. That range runs from DNA methylation clocks and telomere length to blood-chemistry composites and frailty scores. Anyone who follows geroscience will recognize the proposed mechanism. Particles loaded with transition metals and polycyclic aromatic hydrocarbons generate reactive oxygen species. That oxidative load damages mitochondrial DNA, activates the NLRP3 inflammasome, shifts methylation patterns, erodes telomeres and pushes cells into senescence. Senescent cells then release inflammatory signals that push neighboring cells into the same state, so the damage can outlast the exposure.

The more useful finding concerns which measures actually detect this effect. The ones that respond most reliably to pollution are the least glamorous: Klemera-Doubal biological age, blood-based PhenoAge and frailty indices. All of them are built from routine markers such as CRP, albumin, glucose and white cell count. The fashionable epigenetic clocks hold up worse on close inspection. A 2026 meta-analysis of 18 studies and more than 363,000 people found no significant pooled association between long-term pollution and acceleration of the Horvath clock or GrimAge. This held even though most individual studies reported positive results. That pattern usually points to heterogeneity, small-study effects or publication bias rather than a hidden true effect.

Magnitude matters. In the UK Biobank, where the air is relatively clean, an interquartile rise in fine particles was tied to about three weeks of extra biological age. Among older Chinese adults, each additional 10 micrograms of PM2.5 per cubic meter raised frailty risk by about 5 percent. Some headline figures are much larger, such as three extra years of biological age per interquartile rise in ultrafine particles. That figure comes from a single cross-sectional study of COPD patients and should not be generalized.

The review’s boldest claim is that biological aging sits on the causal path from dirty air to disease. In the authors’ own analysis of two cohorts, aging measures statistically accounted for roughly a tenth to a half of the link between pollution and death. Mediation analysis of observational data is fragile, however. Income, smoking and chronic illness all track with both pollution exposure and faster aging.

There is some encouraging news. Chinese households that switched from coal or wood to clean cooking fuel showed slower biological aging and much lower frailty risk. Regions where air quality improved saw slower frailty progression. None of these comparisons were randomized.

The central idea is plausible and important: pollution looks less like a list of separate diseases and more like a general accelerant of aging. The evidence that it moves molecular clocks, the tests biohackers actually buy, is still unconvincing.

Actionable Insights

Indoor air is the part you control, and it shows the clearest harm. Cooking or heating with solid fuels (coal, wood, biomass) carried a pooled 28 percent higher risk of frailty. In one large Chinese cohort, switching to clean fuel cut frailty risk by a third to two thirds. This review does not assess gas stoves or home HEPA filtration. The authors list filtration trials as an unmet research need.

For a typical Western city dweller, the numbers are modest. Each 10 microgram drop in long-term PM2.5 was associated with about 5 percent lower relative frailty risk. If your baseline risk were 15 percent, that change would take it to about 14.3 percent. For one person this is small, but across a population it is large.

The risk curve steepened above about 50 micrograms per cubic meter. Protecting yourself on bad days, such as wildfire smoke or heavy traffic, targets the steepest part of that curve. An N95 mask, staying indoors and running a filter all apply here.

Regular physical activity weakened the frailty risk from solid-fuel exposure and increased the benefit of switching fuels.

Do not use consumer epigenetic clock tests to track pollution effects. At the population level, the noise exceeds the signal.

Wildfire smoke is biomass combustion, so it is chemically close to the household wood and coal smoke the authors discuss than to traffic exhaust. It is rich in organic carbon, black carbon and PAHs, all of which have high oxidative potential.

Context and Source

  • Open Access Paper: Aging in the air we breathe: Mechanisms and consequences of air pollution exposure for biological aging, Published 19 August 2026.
  • Institutions: Tampere University (Faculty of Medicine and Health Technology); Karolinska Institutet; University of Oulu
  • Countries: Finland and Sweden
  • Journal: Ageing Research Reviews
  • Impact evaluation: The impact score of this journal is 15.5, evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a High impact journal.

Leitura Relacionada:

RapAdmin

SkinWoundsSecretome
SkinWoundsSecretome2752×1536 440 KB

This narrative review from the University of Coimbra argues that aged skin heals poorly because oxidative stress, senescent cells, chronic inflammation, weak blood supply and broken cell-to-cell communication all reinforce each other. The authors propose three cell-free fixes: the secretome (the mix of growth factors, cytokines and chemokines that stem and other cells release), extracellular vesicles (EVs, including “exosomes”), and microRNA (miRNA) therapies. They pair these with smart delivery systems such as hydrogels, nanofibers, nanoparticles and microneedles that release their cargo in response to wound conditions. The mechanistic case is strong. The human evidence is thin.

Cut the skin of a 25-year-old and a 75-year-old and you will watch two very different repair jobs. The younger wound moves briskly from inflammation to rebuilding to remodelling. The older one often stalls, sometimes for months. This review sets out to explain why, and what might restart the process without transplanting living cells.

The authors describe aged skin as a system locked in a vicious circle. Skin loses antioxidant capacity with age, so reactive oxygen species build up. That damage harms DNA and mitochondria, which leak more oxidants. Stressed cells switch on the p16 and p53/p21 brakes and become senescent. Senescent cells then secrete an inflammatory cocktail, the SASP, which degrades collagen through enzymes called MMPs and pushes neighbouring cells toward senescence. Thinning blood vessels starve the tissue of oxygen, completing the loop. The result is a wound that cannot leave the inflammatory phase.

The Big Idea is that the repair signals, not the repair cells, are what matter. Stem cells injected into wounds mostly die, yet they still help, largely through what they secrete. So why not deliver the secretions directly? The review sorts candidates into three groups. First, soluble factors: EGF, FGF, PDGF, anti-inflammatory IL-10, and chemokines such as CXCL12. Second, EVs from mesenchymal stromal cells, adipose cells, umbilical cord and induced pluripotent stem cells, which carry proteins and miRNAs in a protective lipid shell. Third, miRNAs themselves. The authors name miR-146a, miR-21 and miR-132 as the best candidates to top up, and miR-155, miR-34 and miR-200 as candidates to block.

Delivery is the practical bottleneck. An aged wound is acidic, protease-rich, oxidant-rich and poorly perfused, which chews up delicate proteins and RNA. The newest platforms react to those conditions. One hydrogel falls apart only when MMP-9 reaches the high levels seen in diabetic wounds, releasing exosomes on demand. Another senses glucose and pH, generates oxygen and scavenges oxidants. Lipid nanoparticles carrying VEGF messenger RNA, the same basic technology behind mRNA vaccines, closed mouse wounds almost completely in nine days.

Timing matters too. In one mouse study, a tiny EV dose given twice daily outperformed single doses up to 100 times larger. Several agents, including IL-10 and an anti-CCL28 antibody, worked at low doses and failed or backfired at high ones. More is not better.

The sobering part is the clinical table. Only four registered human studies of secretome or EV products appear. One small uncontrolled study, one randomized trial in diabetic foot ulcers with a striking result, one burn trial that enrolled a single patient, and one well-designed trial in healthy volunteers that found no benefit at all. The only growth factor approved by the FDA for wounds, PDGF-based Regranex, has been available since the 1990s and has not transformed care.

For readers watching the booming consumer “exosome” market, this review is a useful reality check: the biology is plausible and the preclinical data are abundant, but the evidence that any of this works in an 80-year-old’s leg ulcer does not yet exist.

Actionable Insights

There is nothing here you can buy yet, that is proven to speed healing in older adults. Consumer “exosome” serums and injections are not FDA-approved drugs, and the review’s own evidence base is mostly mice.

The strongest human signal is one randomized trial in diabetic foot ulcers: umbilical cord exosome gel appeared to shorten average time to full healing from about 20 weeks to about 6 weeks. That is a dramatic difference, roughly 70% faster, but it comes from a single trial with notable dropout and needs replication.

For perspective, the approved PDGF gel raised complete ulcer closure from about 35% to about 50% of patients in its pivotal trial, meaning roughly one extra healed ulcer for every seven patients treated. That is a realistic ceiling for a single molecule.

Practical, lower-risk levers the paper touches on: regular exercise reversed slow wound healing in aged mice and prevents blood vessel cell senescence in humans. Because short-lived senescent cells help early healing, people using senolytics may reasonably pause them around surgery or significant wounds, and anyone on rapamycin should discuss perioperative holding with their surgeon, since mTOR inhibition is known to slow wound repair.

Context and Source

  • Open Access Paper: Secretome and bioactive molecules for the enhancement of aged wound healing, published 17 September 2026
  • Institutions: University of Coimbra (CIBB, CNC, MIA-Portugal, Faculty of Pharmacy, Faculty of Medicine, IIIUC), Coimbra University Hospital Centre Plastic Surgery and Burns Unit, and Sanfil Medical Group
  • Country: Portugal
  • Journal: Ageing Research Reviews
  • Impact evaluation: Ageing Research Reviews has a 2025 Journal Impact Factor of 15.5 in the 2026 Journal Citation Reports release, is ranked Q1 in Cell Biology and Geriatrics & Gerontology, and has a CiteScore of 20.6. The impact score of this journal is 15.5, evaluated against a typical high-end range of 0 to 60+ for top general science (and roughly 0 to 20 for ageing and gerontology specialty journals), therefore this is a High impact journal.

Leitura Relacionada:

RapAdmin

Cyclists
Cyclists2752×1536 464 KB

King’s College London researchers re-tested 82 of 125 highly active amateur road cyclists nine years after their first assessment, now aged 64 to 86. Aerobic capacity (VO2peak) fell by 19.7%, about 2.2% per year, which is faster than cross-sectional studies predicted. Lean mass fell 8.1% and fat mass rose 20% while body weight stayed flat. Blood pressure, glucose and lipids stayed normal, and 77 of 78 testable participants remained at or above the 90th percentile for fitness for their age. Only 35 of 82 stayed disease free. Twenty-three developed poorly controlled disease, almost all cardiovascular. This group lost somewhat more fitness but still stayed near the top of the population range.

In 2012 and 2013, researchers at King’s College London put 125 amateur road cyclists aged 55 to 79 through a large battery of physiological tests. The goal was to study aging with inactivity taken out of the equation. Most older adults do too little exercise to meet national guidelines, so it is hard to tell which losses come from time and which come from the sofa. People who could still ride 100 km in under six and a half hours were meant to show what aging looks like when the body stays in use.

Nine years later the team called everyone back. Eighty-two returned, and every one of them was still cycling. Their aerobic capacity had fallen from 44.1 to 35.4 millilitres of oxygen per kilogram per minute. That is a drop of nearly 20 percent, or about 2.2 percent a year. The rate is roughly two and a half times what cross-sectional studies of athletes had predicted, and almost identical to a longitudinal study of master runners from two decades ago. Aging did not spare these committed exercisers.

Most of the drop came from the heart. Maximum heart rate fell by 11 beats per minute, and the oxygen delivered per heartbeat shrank by about 15 percent. Muscle declined too. Lean tissue fell by 4.3 kg and fat rose by 3.3 kg, so the bathroom scale barely moved while body fat climbed from 24 to 29 percent. This hidden shift matters because cycling, the main exercise this group did, puts little load on muscle and bone.

Even so, decline is not the main finding. At follow-up, all but one of the 78 people who completed the exercise test sat at or above the 90th percentile for their age and sex in a large reference database. Blood pressure, glucose, triglycerides and HDL cholesterol barely changed. These riders lost fitness, but they started so high that they finished far above their peers.

The study also shows what they did not escape. Only 35 of the 82 returners remained free of disease. Twenty-three developed poorly controlled illness, 96 percent of it cardiovascular, including coronary disease and aortic dilation. Some of these conditions are more common in long-term endurance athletes. The study cannot say whether riding caused them, prevented something worse, or had no effect. Riders with compromised health lost more fitness, 24 percent against 17 percent in the disease-free group, but still ranked near the top of the population.

There are important caveats. A third of the original cohort did not return, including eight who had died, and those who stayed away had higher blood pressure at the start. The returners are therefore likely the healthiest survivors. There is no inactive comparison group, so the study cannot measure how much exercise slowed decline. It can only show what decline looks like in people who kept exercising. Training volume also fell by a third, which blurs the line between aging and detraining.

The conclusion is sobering rather than triumphant. Exercise does not stop the clock and does not guarantee an old age free of disease. What it does is raise the whole curve. The losses still come, but they start from a much higher point and leave people well above the threshold where daily life becomes difficult.

Actionable Insights

  1. Expect aerobic fitness to fall about 2% per year after 60, even if you train. In this study, staying active kept almost everyone in the top 10% for their age. In large population studies, each extra MET of fitness (one unit of exercise capacity) is linked to about 13% lower death risk. These riders lost 2.5 METs over nine years but still ended at about 10 METs, a level associated with low risk.
  2. Cycling alone did not protect muscle. Lean mass fell by 4.3 kg (8%) and body fat rose by 5.4 percentage points. The body-fat change is a large effect, roughly equal to the typical difference between two random participants at baseline. Add resistance training at least twice a week, and keep protein intake at about 1.0 to 1.5 g per kg per day. Protein intake fell slightly in this cohort.
  3. Don’t rely on the scale. Weight stayed flat while composition worsened. Track body composition with a DEXA scan or at least your waist measurement.
  4. If you are an older, high-volume endurance athlete, get your heart screened. Twenty-seven percent of returners developed poorly controlled disease, mostly cardiovascular. Reasonable checks include an ECG, a coronary calcium score and an aortic assessment. [Confidence: Medium]
  5. Protect your training volume. Riding dropped by a third, and this may explain part of the fitness loss.

Context and Source

  • Open Access Paper: A 9-year longitudinal investigation into physiological aging in highly active older adults, Published: 28 September 2026.
  • Institutions: Centre for Human and Applied Physiological Sciences, King’s College London; MRC-Versus Arthritis Centre for Musculoskeletal Ageing Research, University of Birmingham
  • Country: United Kingdom
  • Journal: GeroScience (Springer; official journal of the American Aging Association).
  • Impact evaluation: Springer lists GeroScience’s 2025 Journal Impact Factor as 6.0. The impact score of this journal is 6.0, evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a Medium impact journal. Within aging and gerontology it is a top-tier specialty outlet.

Leitura Relacionada:

RapAdmin

Microbiota
Microbiota2752×1536 411 KB

Researchers at China Agricultural University took fecal microbiota from healthy human donors aged 22 to 29 and 70 to 85, and transplanted them into antibiotic-depleted Bama miniature pigs. Seven days after colonization, pigs carrying elderly human microbiota showed shorter ileal villi, lower levels of three tight junction proteins across jejunum, ileum and colon, and roughly two and a half times higher circulating diamine oxidase, a blood marker of leaky gut. Plasma metabolite profiles diverged, with five metabolites separating the groups. Cell culture work confirmed that two of those metabolites moved barrier resistance in opposite directions. Ileal gene expression showed a coordinated shutdown of interferon-stimulated genes in the elderly group. The design is correlative at the mechanism level, the sample is six pigs per group, and the observation window is one week.

The idea that an aged gut microbiome is not just a passenger but a driver of age-related decline has been tested mostly in mice. Mice are cheap and tractable, but their gut is a poor stand-in for ours: different fermentation site, different transit, different diet. This study swapped the model. Pigs eat like us, ferment in the colon like us, and their small intestine scales to body weight roughly the way ours does. That makes the result harder to dismiss as a rodent artifact.

The setup was simple. Eighteen two-month-old male miniature pigs were divided into three groups of six. Two groups were emptied out with a three-day antibiotic cocktail, then given alternate-day gavages of human fecal slurry over eight days, drawn either from five young donors or five elderly donors. A third group received nothing. After a week of colonization the animals were euthanized and their intestines examined.

The transplants took. Microbial richness bounced back to baseline, but the community composition was reshaped and the young and elderly communities stayed distinguishable from each other. Pigs given elderly microbiota carried more Blautia obeum, a species previously linked to worsened colitis in mice and to altered glucose handling in humans. Pigs given young microbiota carried more Phocea massiliensis, a species that declines with age in mice and tracks inversely with frailty scores.

The host responded fast. Villi in the ileum, the segment doing most of the final nutrient absorption, were about a fifth shorter in the elderly group. Duodenum, jejunum and colon architecture were unchanged, which argues for a segment-specific vulnerability rather than generalized damage. Tight junction proteins ZO-1, claudin-1 and occludin dropped by roughly a third to a half depending on segment. Diamine oxidase in blood, which rises when the intestinal lining is compromised, climbed sharply.

The metabolite story was the most mechanistically satisfying part. A dipeptide, Tyr-Phe, fell in elderly recipients and correlated positively with tight junction levels. Prostaglandin E3 rose and correlated negatively. When the team applied each to cultured pig intestinal cells, Tyr-Phe raised barrier resistance and prostaglandin E3 lowered it, which is what the correlations predicted.

The transcriptomics complicate the picture. Seven hub genes, all interferon-stimulated, were downregulated in elderly recipients. The authors read this as a weakened baseline antiviral tone in the epithelium. That reading is plausible but not tested here, and it sits awkwardly with the usual inflammaging narrative of an over-activated aged immune system.

Actionable Insights

What the study does is put a number on how quickly a microbial community can degrade barrier function in a human-like gut.

The magnitudes matter more than the p-values. Ileal villus height fell about 21 percent, with a standardized effect size near 1.4. In plain terms, an effect size of 1.4 means the average elderly-microbiota pig sat well outside the range where most young-microbiota pigs clustered. Tight junction protein reductions ran 32 to 47 percent with effect sizes between roughly 2.1 and 3.0, which is very large by the usual convention that 0.8 counts as large. Blood diamine oxidase rose about 146 percent, effect size near 2.0.

The practical reading is that donor age, not the recipient’s age, drove all of this. The pigs were two months old. Whatever the elderly microbial community carried was sufficient to degrade barrier proteins in a young host within a week. That supports the general case for attending to gut community composition, and it puts specific candidates on the watch list: Blautia obeum as a possible liability marker, Phocea massiliensis as a possible favorable one. Neither is measurable on a consumer stool test with any reliability, and neither is modifiable by any validated intervention at present.

There is no lifespan data, no human endpoint, and no tested intervention. Anyone selling a probiotic on the back of this paper is ahead of the evidence.

Context and Source

Leitura Relacionada:

RapAdmin

RapamycinCVD
RapamycinCVD2752×1536 435 KB

Researchers at Leiden University gave rapamycin to naturally aged male mice that already had advanced atherosclerosis. After eight weeks, plaque size, collagen and necrotic core were unchanged. The immune environment was substantially remodeled. Plaque macrophage staining fell about 23 percent. Aortic neutrophils and CD8 T cells dropped. Regulatory T cells rose as a share of helper T cells. Germinal center B cells, antibody levels and age-associated B cells fell sharply in plaque-draining lymph nodes. Some senescence markers declined. The costs were a 25 percent rise in blood cholesterol and broad suppression of antibody-producing immunity.

Rapamycin has spent two decades as the most reliable lifespan-extending drug in mice, and a growing number of people take it off-label hoping to slow their own aging. A new study from Leiden University asks a narrower, clinically pointed question: what does the drug do to the immune system of an old animal that already has advanced arterial disease?

The answer is that it reshapes that immune system substantially, but it does not shrink the plaques.

The team used male mice lacking the LDL receptor, a standard model for human-like cholesterol problems. The mice aged on ordinary chow until they were 80 to 90 weeks old, roughly comparable to people in their late fifties to mid-sixties. By then the animals carried arterial plaques built up slowly over a lifetime rather than forced by a high-fat diet. Half then received rapamycin injections three times a week for eight weeks. The others received a placebo solution.

Plaque size did not change. Neither did collagen content or the necrotic core, the dead, debris-filled center that makes human plaques prone to rupture. What changed was the cellular makeup. Rapamycin-treated plaques held about 23 percent less macrophage staining. Macrophages are the immune cells that swallow cholesterol and become foam cells. In the aortic wall, neutrophils dropped by roughly two-thirds and killer CD8 T cells by more than half. Meanwhile, the share of regulatory T cells, which calm inflammation and are thought to help stabilize plaques, rose from about 57 to 71 percent of helper T cells.

The effects were much larger in the lymph nodes that drain the heart and aorta. There, total immune cell counts fell almost six-fold. Germinal centers are the lymph node sites where B cells learn to make high-affinity antibodies, and they all but disappeared. Blood levels of IgM and several IgG subclasses fell by 40 to 60 percent. Age-associated B cells also declined. These cells accumulate with age and are linked to autoimmunity and chronic inflammation.

Gene expression hinted at a partial rollback of immune aging. Senescence scores fell in several aortic immune cell types. Spleen cells expressed less p16 and Btg2, two hallmarks of aging cells. Two other senescence markers, p21 and p53, did not change.

The trade-offs are real. Blood cholesterol rose 25 percent, a side effect already well documented in transplant patients on mTOR inhibitors. The same suppression of germinal centers and antibodies that looks anti-inflammatory inside an artery could weaken responses to vaccines and infections in an older person. The spleen also showed more interferon-gamma-producing helper T cells, and more helper T cells that had lost CD27, a marker of heavily used, late-stage cells.

The authors present the work as a case for “immune rejuvenation” in older cardiovascular patients, possibly combined with statins to offset the cholesterol rise. The study shows a quieter, more regulated immune landscape around established plaques. It does not show that plaques grew less, or that the mice had fewer cardiac events or lived longer. Those are the outcomes that ultimately matter.

Actionable Insights

This is a short mouse study with no clinical endpoints. It supports hypotheses, not prescriptions. With that caveat, four practical points emerge.

First, do not expect rapamycin alone to shrink existing plaque. What improved was plaque inflammation. Macrophage content fell about 23 percent, a moderate-to-large effect (a treated mouse had roughly a 71 percent chance of scoring better than a control).

Second, monitor lipids. Total cholesterol rose 25 percent, from about 258 to 323 mg/dL. That is a large effect (roughly an 83 percent chance a treated mouse ran higher than a control), and it matches human transplant data. Anyone using rapamycin who has cardiovascular concerns should track an ApoB or lipid panel. Pairing with lipid-lowering therapy deserves a conversation with a clinician.

Third, consider vaccine timing. Germinal center B cells in the draining lymph nodes fell about 97 percent, and IgM fell about 61 percent. This used a fairly intense regimen, and low-dose human trials have shown better vaccine responses, so dose and schedule likely matter.

Fourth, the regulatory T cell shift (up about 13 percentage points) is the most plausible benefit mechanism, but it remains unproven in humans.

Context and Source

RapAdmin

MuscleFibers
MuscleFibers2752×1536 481 KB

Using MRI, standard histology and a high-resolution light microscopy pipeline (FIM-ID), this study measured skeletal muscle at the whole-muscle, fibre and myofibril levels in young and older adults and in young and old mice, including mice with one hindlimb immobilised for 10 days. In both species, age-related shrinkage of fast-twitch (SERCA1-positive, Type II) fibres came mainly from fibres having fewer myofibrils, not from individual myofibrils getting thinner. Disuse in mice worked the same way. Slow (Type I) fibres in humans were spared. The authors conclude that loss of myofibril number is a conserved mechanism of fibre atrophy and a possible therapeutic target.

Every muscle fibre is packed with hundreds to thousands of myofibrils, the protein cables that actually generate force. When a fibre shrinks with age or bed rest, there are two ways it could happen. Each cable could get thinner, or the fibre could carry fewer cables. The field has known for about fifty years that fibres shrink. It has not known which of these two things is going on, mostly because counting myofibrils by electron microscopy is extremely slow work.

A team led by Troy Hornberger at the University of Wisconsin-Madison, working with Christopher Sundberg’s group at Marquette University, now has an answer. They used a light microscopy method they built, called FIM-ID. It images myofibrils with enough contrast for software to trace them automatically. With it they measured muscle at three scales in 34 young and older adults, and in young and old mice. Some of the mice had one hind leg immobilised for ten days.

In people, the top-line result was familiar. Adults aged 65 to 84 had about a third less quadriceps volume on MRI than adults aged 19 to 40. Under the microscope, the fast-twitch Type II fibres were about 23% smaller in older people. Slow Type I fibres were untouched. The new finding came from the smallest scale. Individual myofibrils in the older fast fibres were the same size as in young fibres. What had changed was how many there were, down by roughly a quarter. Missing myofibrils accounted for almost all of the fibre shrinkage.

Mice showed much the same pattern. Old mice had fewer myofibrils per fast fibre. They also had some myofibril thinning, mostly in a muscle rich in a highly glycolytic fibre type (IIb) that humans do not have. Ten days of immobilisation in young mice cut soleus fibre area by about a third. Again, most of that came from losing myofibrils, with only slight thinning of the ones that remained. Old mice lost less muscle when immobilised. The authors think their muscles were already partly deconditioned by low daily activity.

Why does the distinction matter? If ageing muscle thinned every cable evenly, that would point to a general imbalance between protein building and breakdown. Losing whole cables points to something more specific: a failure in myofibril turnover. The muscle may be removing myofibrils whole, failing to build or split new ones, or both. That narrows the target list. It includes the machinery that assembles new myofibrils in response to mechanical load, which this lab has previously shown drives muscle growth.

The caveats are real. The human data are a snapshot comparing different people, not the same people followed over time, so they cannot show the order of events. Only one thigh muscle was biopsied, and about 30 fibres per person were analysed in detail. The myofibril “count” is calculated from areas, not tallied one by one. The study measured structure, not the molecular signals behind it, and it tested no treatment. What it gives is a clean map of where the muscle goes. That map is needed before anyone can design a way to stop the loss.

Actionable Insights

This paper tested no intervention, so everything below is an inference, not a demonstrated benefit.

  1. The loss is large and concentrated. Older adults had about 34% less quadriceps volume. Within each sex, that is a Cohen’s d of about 2, which is very large: the typical older person fell below nearly every young person of the same sex. The damage sat in fast-twitch fibres, which shrank about 23% (d about 0.8, large). Slow fibres were unchanged. Fast fibres supply power, quick reactions and fall recovery.
  2. Train the fibres that are being lost. Walking and light cardio mostly use slow fibres. Heavy or explosive resistance training recruits fast fibres. The case for this comes from the broader exercise literature, not this study. This paper explains why fast fibres are the ones to target.
  3. Treat disuse as structural damage. In young mice, 10 days of immobilisation removed 23% to 35% of mass in several leg muscles. Most of that loss was whole myofibrils, which have to be rebuilt rather than simply refilled. After injury or surgery, keep unloading periods short and start loading as early as your clinician allows.
  4. Old muscle lost less during immobilisation only because it started lower. That is not protection.

Context and Source

  • Open Access Paper: Macroscopic to ultrastructural analyses identify the loss of myofibrils as the primary mediator of ageing- and disuse-induced muscle fibre atrophy
  • Institutions: University of Wisconsin-Madison (Department of Comparative Biosciences; Division of Geriatrics and Gerontology) and Marquette University (Exercise and Rehabilitation Sciences), with an affiliation at Sohag University, Egypt
  • Country: USA
  • Journal: The Journal of Physiology (published online 25 September 2026)
  • Impact evaluation: The journal’s publisher page currently lists a CiteScore of 7.2 and a Journal Impact Factor of 4.6. The impact score of this journal is 4.6 (JIF), evaluated against a typical high-end range of 0-60+ for top general science, therefore this is a Medium impact journal.

Leitura Relacionada:

RapAdmin

skinseno
skinseno1920×1072 310 KB

This narrative review from Shenzhen University argues that senescent cells are central to skin aging. It covers four skin cell types (fibroblasts, macrophages, keratinocytes and epidermal stem cells), how damage from UV-driven oxidative stress and DNA damage spreads between cells through the SASP and extracellular vesicles, and how histone modifications keep aged skin macrophages in an inflammatory state. It then surveys interventions: senolytics (navitoclax, dasatinib plus quercetin, fisetin), senomorphics (rutin, rapamycin, metformin), stem cell and secretome therapies, nanocarrier delivery, and machine-learning senolytic discovery. It contains no new data. Most of the evidence it summarizes comes from cell culture, rodents and human skin grafted onto mice. The human trials it cites are small, short, and mostly split-face cosmetic studies.

Skin shows age sooner than any other organ, and the authors argue it shows it for a specific reason: old, damaged cells that refuse to die.

These are senescent cells. They stop dividing but stay metabolically active, and they release a cocktail of inflammatory signals, enzymes and small vesicles known as the senescence-associated secretory phenotype, or SASP. In skin, the review says, the main senescent populations are fibroblasts in the dermis, keratinocytes in the outer layer, immune macrophages, and the stem cells that normally replenish the epidermis and hair follicles.

Each population fails differently. Senescent fibroblasts make less collagen and more of the matrix metalloproteinases (MMPs) that break collagen down. The authors describe a feedback loop: fragmented collagen reduces the mechanical tension fibroblasts feel, which raises their internal oxidative stress, which drives further MMP production. Senescent keratinocytes renew the epidermis more slowly, thinning the barrier and letting moisture out and bacteria such as Staphylococcus aureus in. Aged macrophages get stuck in an inflammatory mode and fail to shift into the repair mode that heals wounds.

The review’s more unusual contribution is its attention to how the damage spreads. Senescent cells release more extracellular vesicles than young cells. UV-damaged cells may export fragments of their own DNA in these vesicles, and neighboring cells detect the foreign DNA through the cGAS-STING immune sensing pathway and become senescent in turn. Vesicles also carry microRNAs, such as miR-30a, that suppress renewal in young keratinocytes. The authors also compile evidence that epigenetic regulators, including the enzymes JMJD3, MOF and SETDB2, lock macrophages into a chronic inflammatory state. Much of that evidence, however, comes from diabetic wounds rather than aged skin.

On treatments, the authors cover the familiar longevity pharmacopeia. Navitoclax clears senescent dermal fibroblasts in mouse and human-skin-graft models but causes low platelet and neutrophil counts when taken systemically. Dasatinib plus quercetin, and fisetin alone, reduce senescent fibroblast counts in similar models. Rutin, a quercetin glycoside, acts more as a SASP dampener than a cell killer. Topical rapamycin gets a mention for one small human trial that found fewer p16-positive cells and more collagen VII. Metformin is included for AMPK activation, mostly on the strength of rodent and worm data.

Stem cell therapy receives equal emphasis. The authors conclude that cell-free products, meaning conditioned media and vesicles from mesenchymal stem cells, are more practical than transplanted cells, which survive poorly after injection. Seven clinical studies are tabulated, and nearly all delivered the product by microneedling.

The review ends by pointing to machine-learning screens that have identified new senolytics, including ginkgetin, periplocin and oleandrin, from compound libraries.

The big idea is coherent: skin aging is a senescence problem that can be spread from cell to cell, and so it should be treatable by removing or silencing senescent cells locally. The weakness is that this remains a hypothesis supported mainly by mechanistic and animal work. The human data are sparse, small and unblinded or confounded more often than not.

Actionable Insights

The most reliable intervention remains the least exotic one. The review repeats a common estimate that UV exposure causes about 80% of visible skin aging. That figure is widely cited but loosely sourced, and the true share is hard to measure. Daily broad-spectrum sun protection is still the highest-return step.

Among topicals discussed, two have small human trials:

  • Rutin cream: In a 40-person, 4-week double-blind study, crow’s feet length fell by about 24% and crow’s feet area by about 27% in the rutin group. These are improvements from each person’s own baseline. The paper did not report a standardized effect size, and 4 weeks is too short to judge durability.
  • Topical rapamycin: In a hand-to-hand comparison, rapamycin cream lowered the senescence marker p16 and raised collagen VII.

Stem cell conditioned media trials all used microneedling, which stimulates collagen on its own. The one trial that compared delivery methods found no difference between groups. Any added benefit from the stem cell product itself remains unproven.

Oral senolytics (fisetin, dasatinib plus quercetin) have no controlled human skin-aging outcome data in this review.

Context and Source

  • Full title: Skin Aging: From Molecular Mechanisms to Therapeutic and Technological Innovations
  • Institution: Medical School, Shenzhen University; Laboratory of Regenerative Medicine, The 2nd Affiliated Hospital of Shenzhen University
  • Country: China
  • Journal: Journal of Cellular and Molecular Medicine
  • Impact evaluation: The impact score of this journal is 4.7, evaluated against a typical high-end range of 0–60+ for top general science, therefore this is a Medium impact journal.

Leitura Relacionada:

RapAdmin

NMN
NMN2752×1536 437 KB

A large, long-running Harvard-led mouse study gave middle-aged mice a high dose of the NAD+ precursor NMN in their drinking water for the rest of their lives. Both sexes accumulated frailty more slowly. Only females lived longer: median lifespan rose by 8.5%. Males got leaner and more active but did not live longer, and their tissues showed more inflammation. The authors also report that NMN caused a more than tenfold rise in a gut bacterium, Anaerotruncus colihominis, which can itself take up NMN, and they argue it helps explain the health benefits. This is a revised, not-yet-peer-reviewed preprint of work first posted in 2024. The female control mice were short-lived, so the lifespan result may reflect a correction of poor baseline health rather than slower aging.

For a decade, NMN has been sold as an anti-aging molecule on the strength of mouse and cell studies that never answered the one question that matters most: does it make a mammal live longer? This study, led by Alice Kane and David Sinclair, is the first serious attempt to answer it, and the answer is a qualified “sometimes.”

The team started C57BL/6 mice on NMN at 13 months of age, roughly the human equivalent of the early 40s. The dose was about 550 mg per kilogram per day, which scales to roughly 3 grams a day for a 70 kg adult, two to three times what human trials usually use. Several hundred mice were followed until natural death, with subsets pulled for health testing and tissue analysis.

The clearest finding is on frailty. Using a 31-item checklist of age-related decline (fur loss, hunched posture, hearing and vision loss, breathing changes), treated mice of both sexes scored better at 18.5 and 21 months. The gain amounts to roughly two and a half months of delayed frailty accumulation.

Lifespan is where the sexes split. Treated females lived about 8.5% longer at the median and 7.9% longer at the 90th percentile. Males showed early separation of survival curves that faded to nothing. Autopsies found no change in tumor burden, which addresses a long-running worry that NAD+ boosters might feed cancer. They did find slightly more kidney inflammation in treated mice.

Males, meanwhile, got the metabolic benefits. They gained less fat in late middle age, burned relatively more fat, and ran around more at night. Yet their liver, muscle and fat tissue showed a gene expression pattern that looked older, not younger: more inflammatory and interferon signaling, less mitochondrial activity. Levels of CD38 and several PARP enzymes, which consume NAD+, went up in males but not females. The authors propose that males burn through the extra NAD+ on DNA repair and inflammation, while females route it into mitochondria. That is a plausible story, but it remains a hypothesis.

The gut microbiome adds a new layer. Isotope tracing suggests that much oral NMN is broken down and reprocessed by gut bacteria before the body uses it. A. colihominis, a butyrate producer previously linked to lower neuroinflammation and enriched in human centenarians, jumped more than tenfold with treatment, and the bacterium took up labelled NMN in culture. The authors float an A. colihominis probiotic as a partner to NAD+ precursors.

The big caveat is the controls. The untreated females died at a median of roughly 26 months, around 790 days. A widely used benchmark holds that healthy lab mice should reach about 900 days before a lifespan gain can be credited to slower aging. Even the NMN-treated females fell short of that line. The more cautious reading is that NMN helped unhealthy female mice catch up toward a normal lifespan. That still matters, since many humans age in less-than-ideal conditions, but it is not the same thing as slowing aging.

Actionable Insights

  • NMN is not a proven lifespan drug. In this study it extended life only in female mice whose untreated lifespan was below normal, and not in males whose controls lived about as long as healthy mice should. The earlier NIH test of a closely related molecule, nicotinamide riboside, found no lifespan benefit in either sex.
  • The most consistent benefit was slower frailty. Treated mice of both sexes carried roughly 1 to 1.7 fewer age-related deficits out of 31. The average treated mouse was less frail than about 74% (males) to 82% (females) of untreated mice. That is a moderate-to-large effect in mice, but it did not show up in grip strength, nest building, or DNA methylation clocks.
  • In males, fat mass at 24 months was about 30% lower in relative terms (roughly 14.5% vs 21% body fat), based on only 7 mice per group.
  • The mouse dose equates to about 3 g per day in humans, well above typical supplement doses. At that dose, treated mice had slightly more kidney inflammation. [Confidence: Medium]
  • Sex may matter. Men and women could respond differently, and no human data yet tests this.
  • Your gut bacteria may help determine how much NMN you actually use.

Context and Source

  • Open Access Paper (Preprint): Long-term NMN treatment increases lifespan and healthspan in mice in a sex dependent manner
  • Institutions: Blavatnik Institute, Harvard Medical School (lead) and the Institute for Systems Biology, Seattle, with contributors from the University of Pennsylvania, Brown University, the University of Rhode Island, NIA/NIH, UNSW Sydney, UT Health San Antonio, ETH Zurich and others
  • Country: United States (lead), with Australian, Swiss and Austrian collaborators
  • Journal: None (preprint server)